I am/have/had
I am looking for
Advanced Filters
Found 172 clinical trials
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
It is a multicenter, open-Label, randomised phase 2 study to compare the efficacy and safety study of R2-MTX chemotherapyLenalidomide, Rituximab and Methotrexatewith R-MTX chemotherapyRituximab and Methotrexate as first-line regimens in the treatment of newly diagnosed primary central nervous system lymphoma.2-year Progression free survival (PFS) is the primary endpoint.
measurable disease
estimated creatinine clearance
renal function
platelet count
primary cns lymphoma
- 0 views
- 19 Feb, 2024
- 1 location